NAMS Stock Overview
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
NewAmsterdam Pharma Company N.V. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$22.70 |
52 Week High | US$26.35 |
52 Week Low | US$5.63 |
Beta | 0.021 |
1 Month Change | 2.90% |
3 Month Change | 98.60% |
1 Year Change | 69.91% |
3 Year Change | 127.91% |
5 Year Change | n/a |
Change since IPO | 110.19% |
Recent News & Updates
Shareholder Returns
NAMS | US Biotechs | US Market | |
---|---|---|---|
7D | 2.5% | -0.5% | 0.6% |
1Y | 69.9% | 9.6% | 29.5% |
Return vs Industry: NAMS exceeded the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: NAMS exceeded the US Market which returned 29.5% over the past year.
Price Volatility
NAMS volatility | |
---|---|
NAMS Average Weekly Movement | 14.6% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NAMS's share price has been volatile over the past 3 months.
Volatility Over Time: NAMS's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 29 | Michael Davidson | https://www.newamsterdampharma.com |
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, an oral and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
NewAmsterdam Pharma Company N.V. Fundamentals Summary
NAMS fundamental statistics | |
---|---|
Market cap | US$2.03b |
Earnings (TTM) | -US$176.94m |
Revenue (TTM) | US$14.09m |
143.8x
P/S Ratio-11.5x
P/E RatioIs NAMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NAMS income statement (TTM) | |
---|---|
Revenue | US$14.09m |
Cost of Revenue | US$0 |
Gross Profit | US$14.09m |
Other Expenses | US$191.03m |
Earnings | -US$176.94m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.98 |
Gross Margin | 100.00% |
Net Profit Margin | -1,255.76% |
Debt/Equity Ratio | 0% |
How did NAMS perform over the long term?
See historical performance and comparison